Aim: The effectiveness and safety of hydroxychloroquine (HCQ) have not been fully validated in Japanese patients with systemic lupus erythematosus (SLE) in the clinical setting. This study evaluated the short-term effectiveness and continuation rate of HCQ therapy in Japanese patients with SLE in the clinical setting for 12 months.
Against Rheumatism recommendations. 3, 4 Furthermore, based on the various benefits demonstrated with these agents, including prevention of organ damage progression, 5, 6 prevention of relapse, 7 improvement of prognosis, 8 prevention of thrombosis, 9 mitigation of infection risk, 10 and improvement of lipid profile, 11 the use of antimalarial agents has recently been recommended for all patients with SLE. 12 However, in Japan antimalarial agents have long been unavailable for use in clinical practice. Recently emerging targeting treatments have been developing. 13 Although HCQ has been used as a mainstay in the treatments of SLE all over the world, patients in Japan have lost the opportunity to receive this treatment. HCQ was approved recently (July 2015) and is yet to be fully validated for its effectiveness and safety in the clinical setting. Furthermore, effectiveness of HCQ either as a concomitant medication in the remission induction phase, as a maintenance therapy with a small dose of corticosteroid (CS), or as a monotherapy without CS remains unclear in patients with SLE. Accordingly, in the present study, we evaluated HCQ therapy with or without CS in Japanese patients with SLE in the clinical setting for 12 months, with a focus on its effectiveness and continuation rate.
| PATIENTS AND METHODS

| Patients
The study included 122 patients diagnosed as having SLE according to the ACR diagnostic criteria established in 1997 or the new Systemic Lupus International Collaborating Clinics diagnostic criteria proposed in 2012, whose course was followed for at least 12 months after the introduction of HCQ therapy at our hospital and affiliated institutions, during the period from the domestic launch of HCQ in September 2015 through to December 2016. All patients underwent ophthalmologic examination before the introduction of HCQ to confirm that they had no retinopathy or maculopathy before HCQ therapy initiation. The Human Ethics Review Committee of our university reviewed and approved this study. All persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under the study were omitted.
| Clinical measurement
To evaluate the short-term effectiveness and safety of HCQ therapy in Japanese patients with SLE in the clinical setting, the primary endpoint was specified as the continuation rate up to 12 months after the introduction of HCQ in all 122 patients with SLE enrolled in this study. The secondary endpoints were changes in the SLE Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group (BILAG) index, anti-double-stranded DNA (anti-dsDNA) titer (U/mL), and serum complement activity (CH50, U/mL) up to 12 months, as well as the effect on concomitant CS dose reduction.
The study further evaluated the effectiveness of HCQ as a concomitant drug in CS-based remission induction therapy or maintenance therapy, as well as the effectiveness of HCQ monotherapy. Therapy with a CS at a prednisolone (PSL) equivalent dose of 0.6 mg/kg or greater was defined as remission induction therapy; therapy with a CS at a dose outside the definition of remission induction therapy was defined as maintenance therapy; and therapy without a CS at the introduction of HCQ, regardless of the use of an immunosuppressant, was defined as HCQ monotherapy.
The new occurrence of one or more items of BILAG category A or two or more items of BILAG category B during the course, requiring a dose increase of concomitant CS, was defined as relapse.
| Statistical analysis
Data are expressed as mean ± standard deviation. The Steel-Dwass test was used to detect statistically significant differences between baseline data and those measured at months 3, 6 and 12. All
reported P values were two-sided and were not adjusted for multiple testing. The level of significance was set at P < 0.05. All analyses were conducted using JMP version 10.0 (SAS Institute Inc., Cary, NC, USA). For statistical analysis, data from discontinued cases were complemented using the "last observation carried forward" method. The continuation rate up to 12 months after the introduction of HCQ, evaluated as the primary endpoint, was 79.5% (97 of 122 patients); HCQ was discontinued in 25 patients ( Figure 1 ). The reasons for discontinuation and the adverse events are summarized in 18.4 ± 11.6, 11.5 ± 6.97 and 7.86 ± 5.54 at 0, 3, 6 and 12 months), respectively, indicating a significant reduction at and after 3 months. (1) Gastrointestinal symptom (1), malaise/blood pressure increase/insomnia/ headache/tremor (1) Gastrointestinal symptom (1), platelet count decrease/bad mood (1), photophobia/ blurry vision (1)
| RESULTS
| Baseline characteristics
| Effectiveness of HCQ therapy as a concomitant drug in remission induction therapy
Mo 5
Diarrhea (1) Diarrhea (1) Mo 6 Pruritus (1) Pruritus (1) dose (PSL equivalent) was 5.37 ± 2.99, 5.26 ± 5.14, 5.68 ± 8.47, and 5.85 ± 7.85 mg/day at 0, 3, 6, and 12 months (as observed analysis:
5.37 ± 2.99, 5.36 ± 5.39, 5.84 ± 8.98 and 6.04 ± 8.31 at 0, 3, 6 and 12 months), respectively, indicating no effect in dose reduction ( Figure 3B ).
| Effectiveness of HCQ monotherapy
In 44 patients for whom HCQ was initiated without concomitant CS, the SLEDAI was 5.00 ± 3.50, 4.30 ± 3.89, 3.41 ± 3.61, and 3.32 ± 3.74 at 0, 3, 6, and 12 months (as observed analysis:
5.00 ± 3.50, 3.83 ± 3.32, 2.75 ± 2.68 and 2.64 ± 2.86 at 0, 3, 6, 12 months), respectively, indicating a significant improvement. Similarly, the BILAG index was 3.27 ± 3.57, 2.77 ± 3.88, 2.38 ± 3.40, and 2.61 ± 3.55 at 0, 3, 6, and 12 months (as observed analysis:
3.27 ± 3.57, 2.35 ± 3.38, 1.86 ± 2.62 and 2.19 ± 2.89 at 0, 3, 6 and 12 months), respectively, demonstrating a significant improvement at and after 3 months. The anti-dsDNA antibody titer was 17.3 ± 32.5, 
| DISCUSSION
In the present study, we introduced HCQ therapy in 122 Japanese patients with SLE and followed them for 6 months to assess the treatment continuation rate and the improvement of disease activity. Our results confirmed a high continuation rate of HCQ therapy in Japanese patients with SLE. In addition, HCQ therapy led to improvement of SLE with highly active SLE and to determine whether or not to continue the HCQ therapy. There were also some patients for whom HCQ was discontinued because of eye symptoms; however, no abnormal findings were identified in examinations by an ophthalmologist in any of these patients. However, it should be noted that the incidence of retinopathy under HCQ therapy is often reported to increase as the dose and treatment period increase. 15, 16 This may mean that ocular safety cannot be evaluated in a short follow-up period as in the present study. Further research will be required to accumulate evidence of the long-term safety, including the risk of retinopathy, in Japanese patients with SLE.
The evaluation of disease activity in 122 patients with SLE demonstrated a significant reduction in the SLEDAI and BILAG index scores at and after 3 months.
Considering the differences in the background characteristics of patients, including disease activity, organ damage, and concomitant CS dose, we separately analyzed the effectiveness of HCQ as a concomitant drug in remission induction therapy and in maintenance therapy, and as monotherapy.
In remission induction therapy, the SLEDAI, BILAG index, antidsDNA antibody titer, and CH50 all significantly improved at and after 3 months along with a significant reduction in the concomitant CS dose. In 49 patients in whom HCQ was initiated during CS-based maintenance therapy, the SLEDAI, BILAG index, anti-dsDNA antibody titer, and CH50 significantly improved. Nevertheless, HCQ did not lead to a significant reduction of the concomitant CS dose. Considering the fact that disease activity and anti-dsDNA antibody titer significantly improved, the lack of significant effects on the reduction of concomitant CS dose is likely attributable to the impact of relapse, that is, inclusion of three patients who required a substantial increase in CS dose in this study. Future accumulation of data from many patients and an extended follow-up period will provide details on the effect of HCQ on CS dose reduction during CS-based maintenance therapy.
Similarly, in 44 patients who received HCQ monotherapy, the SLEDAI and BILAG index significantly improved and the anti-dsDNA antibody titer significantly decreased. The serum complement activity did not indicate a significant increase probably because the level was already normal at the initiation of HCQ.
In summary, the results of this study suggest that, with attention to potential adverse events immediately after initiation, HCQ may be useful as a mainstay of SLE therapy in Japanese patients, either as a concomitant medication in the remission induction phase, as maintenance therapy, or as monotherapy. However, a limitation of this study was that the follow-up period was insufficient to evaluate long-term outcomes, including the effect of HCQ on the prevention of relapse and organ damage or on prognostic improvement. Future accumulation of data from a larger number of patients and continued follow-up is warranted to evaluate the proper effectiveness of HCQ in Japanese patients with SLE.
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